radiation reduction, cost savings and clinical usefulness of abdominal digital tomosynthesis in the evaluation of renal and proximal ureteral stones relative to stone protocol non-contrast computed tomography (NCCT). The aim of this study is to report on our early clinical experience using pelvic digital tomosynthesis for the evaluation of distal ureteral stones as well as to describe the effective dose (ED) and organ specific doses (ODs) for this technique compared to NCCT.
INTRODUCTION AND OBJECTIVES:
The PET radiotracer [18F]-fluciclovine was recently approved by FDA and CMS for detection of metastases in the setting of recurrence after primary treatment for prostate cancer and is undergoing rapid adoption; however, its potential to improve staging and decisions prior to treatment for initial staging has not yet been characterized. We sought to evaluate the potential for fluciclovine-PET to enhance care decisions in the setting of newly diagnosed, high-risk prostate cancer, where standard imaging has suboptimal sensitivity for detecting metastases.
METHODS: Patients with AUA defined high-risk or unfavorable intermediate-risk prostate cancer and clinically localized disease on CT and/or MRI and bone scan already scheduled for robot assisted radical prostatectomy with extended pelvic lymph node dissection (RARP-EPLND) were eligible for this IRB-approved trial. Patients underwent fluciclovine PET-CT according to study parameters. RARP-EPLND with anatomic lymph node packets sent individually was then performed. Histologic findings of metastatic lymph nodes in patients and within specific packets (left pelvic, right pelvic, presacral and nonregional) were then compared to the pre-surgery fluciclovine PET-CT findings to calculate sensitivity and specificity.
RESULTS: 38 patients underwent fluciclovine PET-CT and 35 patients underwent surgery. Mean age was 61.7yrs, mean PSA was 24.4, and median Gleason score was 4þ4. Fluciclovine PET-CT showed suspected extraprostatic disease in 15 patients (39.5%). Three patients were found to have extensive disease on fluciclovine PET-CT and determined to have metastatic disease (confirmed on biopsy, standard of care MRI for bone or clinical response to ADT) and therefore did not undergo surgery. Of the 35 patients undergoing surgery 18/35 (51.4%) had metastatic nodes on histology with fluciclovine PET detecting nodes in 10/18 (55.6%) of these patients for a calculated sensitivity of 61.9%, specificity of 88.2%, PPV of 86.7%, and NPV of 65.2%, with overall accuracy of 73.7%. Diagnostic performance at the lymph node packet level demonstrated a sensitivity of 62.2%, specificity 97.1%, PPV 88.5%, NPV 87.7%, and overall accuracy 87.9%.
CONCLUSIONS: Fluciclovine PET-CT appears to be a valuable tool for pre-treatment staging of patients with high-risk prostate cancer with a high specificity for detection of metastatic lymph nodes. Fluciclovine PET-CT may help in decision-making for treatment options and help guide lymph node dissection during surgery. 
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INTRODUCTION AND OBJECTIVES:
While radical prostatectomy (RP) renders good cancer control, urinary incontinence (UI) remains a major morbidity issue and significantly influences the postoperative quality of life. With the possibility of predicting the chances of UI, urologists receive an important tool in their prognostic armamentarium, which will influence consulting and treatment strategies. The aim of the study was to use data from routine preoperative MRI to estimate the risk of incontinence after RP.
METHODS: We analyzed patients who underwent robotassisted RP for localized prostate cancer at our institution between July 2015 and April 2017. Preoperatively, all patients received a multiparametric MRI of the prostate (3 Tesla Siemens Magnetom). Prospectively collected questionnaires regarding UI were evaluated one year postoperatively (ICIQ-Score). "Tissue 4D" software from Siemens on "Syngo Multimodality Workplace" was used to measure the contrast media (CM) kinetics (median initial area under the curve for the first 60 seconds after injection of CM [median iAUC]). With this technique, we were able to visualize the preoperative perfusion quality of the pelvic floor (levator ani muscle) in comparison to the surrounding pelvic muscle structures (reference). Outcomes were dichotomized into groups "continent" (ICIQ-score [ 0-5) and "incontinent" (ICIQ-score > 5). In each patient, we determined the ratio between the median iAUC of the levator ani muscle to the median iAUC of the surrounding pelvic muscle structures. The resulting perfusion ratios among the group of continent patients were then compared to the ratios of the incontinent patients.
RESULTS: In total 42 patients were included in this study (n[22 in "continent", n[20 in "incontinent" group) . The groups did not differ with regard to clinically relevant characteristics (age, PSA, Gleason-Score and nerve sparing). The perfusion ratio from the continent group was significantly higher than the one from the incontinent group (1.61 vs. 1.15, respectively; difference in perfusion ratios [ 0.45; 95% confidence interval (CI): 0.09 -0.81, p [ 0.015). A further analysis of excellent outcomes (ICIQ [ 0) vs. poor outcomes (ICIQ > 10) of 10 patients in each group, the perfusion ratio of excellent outcomes was also significantly higher (1.48 vs. 0.94, respectively; difference in perfusion ratios [ 0.53; 95% CI: 0.04 -1.03, p [ 0.036).
CONCLUSIONS: Our data demonstrate a promising new strategy to assess the perfusion of pelvic muscle structures with CM kinetics to predict continence after RP. This may facilitate preoperative patient consulting and decision making.
